Jacy Fang

This study identifies a novel CD8+ TIL subset that uses lymphotoxin and IFN pathways to kill cancer cells, linking LTB expression to clinical response in melanoma.

This study shows that targeting CD38 improves T cell function and restores response to immunotherapy in melanoma models.

This study investigates the combination of TLR8 agonism and PD-1 blockade in HNSCC patients, finding increased innate immune activation and dendritic cell-T cell interactions.

DrugMap quantitatively analyzes cysteine ligandability across 416 cancer cell lines, revealing redox state, conformational changes, and mutations as drivers of variability, and identifies covalent inhibitors targeting NFκB1 and SOX10.